Stockreport

Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm cohort of [Read more]